Clinical trials: First-line Treatment
Kawasaki Disease
Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
This study evaluates the efficacy of the addition of infliximab to conventional initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in early regression of coronary artery lesion in patients with Kawasaki disease…
- Trial name
- NCT04535518
- Testing
- IVIG, Aspirin, Infliximab
- Where
- 5 sites in China
- Sponsor
- Children's Hospital of Fudan University
PTLD, Posttransplant Lymphoproliferative Disorder
Risk Stratified Sequential Treatment for CD20-positive PTLD
This phase-II trial will investigate the efficacy, safety and the tolerability of a sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of R-CHOP chemotherapy in patients with CD20+…
- Trial name
- PTLD-1/3 (NCT00590447)
- Testing
- rituximab monotherapy, sequential R-CHOP
- Where
- 7 sites in Australia, Belgium and 5 more
- Volunteers
- 152 people
- Sponsor
- Charite University, Berlin, Germany
Post-operative Endophthalmitis
Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis
One useful effect of early intravitreal corticotherapy is to diminish inflammatory complications after endophthalmitis, which may cause, at least in part, serious complications (retinal detachment, macular edema) which are, more…
- Trial name
- Endophtalmitis (NCT01768078)
- Testing
- Intravitreal injection of Betamethasone + antibiotics, Intravitreal injection of antibiotics
- Where
- 6 sites in France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Metastatic Melanoma
Taxoprexin Treatment for Advanced Skin Melanoma
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00249262
- Testing
- Taxoprexin
- Volunteers
- 30 people
- Sponsor
- American Regent, Inc.
Acute Lymphoid Leukemia Relapse, Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia
The purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and…
- Trial name
- Vandevol (NCT01279096)
- Testing
- Clofarabine
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Lille
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech
Neuroblastoma
Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as topotecan, vincristine, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392340
- Testing
- filgrastim, doxorubicin hydrochloride, topotecan hydrochloride
- Where
- 11 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Children's Cancer and Leukaemia Group
Lung Cancer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.
- Trial name
- REFLECT (NCT04031898)
- Testing
- Non Interventional
- Where
- Bulgaria
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Crohn Disease
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.
- Trial name
- FMT (NCT05321758)
- Testing
- Fecal Microbiota Transplantation, Immunosuppressive Agents
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Acute Rhinosinusitis
Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)
This study was conducted to compare the effectiveness and safety of mometasone nasal spray once daily or twice daily with amoxicillin or with placebo in treating the signs and symptoms of acute rhinosinusitis.
- Trial name
- NCT00750750
- Testing
- mometasone furoate nasal spray (MFNS), MFNS, Amoxicillin
- Volunteers
- 981 people
- Sponsor
- Organon and Co
Breast Cancer
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment.
- Trial name
- NCT00684216
- Testing
- capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Pediatric Crohn's Disease
Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease
Crohn's disease (CD) is an incurable debilitating disorder affecting an increasing number of children. The etiology remains elusive, but a genetically determined aberrant immune response against microbiota appears to be…
- Trial name
- NCT01752790
- Testing
- Top-down, Step-up
- Where
- Italy
- Sponsor
- University of Roma La Sapienza
Acute Graft-versus-host Disease
Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease
This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell…
- Trial name
- NCT07576010
- Testing
- RUX+Steroids
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Daihong Liu
Lung Cancer (NSCLC)
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns.
- Trial name
- NCT07596524
- Testing
- Observation
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
This is a single arm, open-label, multi-center clinical trial to evaluate the efficacy and safety of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil-based chemotherapy plus cetuximab for…
- Trial name
- NCT02717923
- Testing
- maintenance treatment with capecitabine plus cetuximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Huazhong University of Science and Technology
Uveitis
First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial
The proposed study is a masked trial, with stratified block randomization by site, designed to determine which treatment, methotrexate or mycophenolate mofetil, is more effective as first-line steroid-sparing treatment for…
- Trial name
- FAST (NCT01232920)
- Testing
- Methotrexate, Mycophenolate mofetil
- Where
- 2 sites in India
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
PTCL, Gemcitabine
GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL
Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. There is no standardized treatment protocol for this kind of lymphoma.
- Trial name
- NCT03884205
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shandong Provincial Hospital
Uveitis
Methotrexate and Mycophenolate Mofetil for UVEITIS
In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a…
- Trial name
- FAST (NCT01829295)
- Testing
- Mycophenolate mofetil, Methotrexate, Prednisone
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 216 people
- Sponsor
- University of California, San Francisco
Hodgkin Lymphoma
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory…
- Trial name
- ANIMATE (NCT03337919)
- Testing
- Nivolumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- University College, London